论文部分内容阅读
本研究是为了比较应用CC失败的PCOS病人中使用hMG或卵泡刺激素(FSH)的临床结果。研究对象需具备下列PCOS诊断标准;月经稀少或闭经;经期后LH;FSH为3:1,血清睾酮和雄烯二酮水平升高:盆腔B超检查可见多囊卵巢;至少有3个治疗周期,CC应用200mg/d×5天,根据血孕酮值无排卵,以及治疗前12个月检查精液分析,腹腔镜检查正常。在促性腺激素(GH)治疗周期开始,纪录病人的身高,体重和体重指数(BMI),随机每日肌注FSH,hMG或隔日FSH,完成hMG41个治疗周期后改用皮下脉冲FSH。每个治疗周期开始对卵巢作B超检查;每天取血测定雌二醇(E_2)和回顾性测定治疗周期中孕酮(P)值,当E_2>800pmol/L水平时,每侧行卵巢扫描,记录每1侧卵巢中直径>15mm卵泡的数目。所有治疗组经1周治疗后,若血清水平E_2无影响,增加GH剂量;当卵巢产生反应时,治疗剂量不再增加。当优势卵泡
This study was designed to compare the clinical outcomes of hMG or follicle stimulating hormone (FSH) in PCOS patients who have failed CC. Subjects should have the following diagnostic criteria for PCOS; menorrhagia or amenorrhea; menstrual LH; FSH is 3: 1, serum testosterone and androstenedione levels increased: pelvic ultrasound B seen polycystic ovary; at least 3 cycles of treatment, CC application 200mg / d × 5 days, no ovulation according to the blood progesterone value, and check the semen analysis 12 months before treatment, laparoscopy was normal. At the beginning of the gonadotropin (GH) treatment cycle, the patient’s height, weight, and body mass index (BMI) were recorded. Randomized intramuscular FSH, hMG, or every other day FSH were administered. Subcutaneous pulsed FSH was switched to after 41 hMG cycles. Each treatment cycle began to B-ultrasound of the ovary; daily blood estradiol (E_2) and retrospective determination of the treatment cycle progesterone (P) value, when the E_2> 800pmol / L level, ovarian scan on each side Record the number of follicles> 15 mm in diameter on each side of the ovary. All treatment groups after 1 week of treatment, if the serum level of E 2 no effect, increase the GH dose; when the ovary response, the treatment dose is no longer increased. When the dominant follicle